108 related articles for article (PubMed ID: 28667027)
1. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.
Alagkiozidis I; Gorelick C; Shah T; Chen YA; Gupta V; Stefanov D; Amarnani A; Lee YC; Abulafia O; Sarafraz-Yazdi E; Michl J
Ann Clin Lab Sci; 2017 May; 47(3):271-281. PubMed ID: 28667027
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.
Sarafraz-Yazdi E; Gorelick C; Wagreich AR; Salame G; Angert M; Gartman CH; Gupta V; Bowne WB; Lee YC; Abulafia O; Pincus MR; Michl J
Ann Clin Lab Sci; 2015; 45(6):650-8. PubMed ID: 26663795
[TBL] [Abstract][Full Text] [Related]
3. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.
Thadi A; Gleeson EM; Khalili M; Shaikh MF; Goldstein E; Morano WF; Daniels LM; Grandhi N; Glatthorn H; Richard SD; Campbell PM; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2020 Sep; 50(5):611-624. PubMed ID: 33067207
[TBL] [Abstract][Full Text] [Related]
4. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
Reeves PM; Abbaslou MA; Kools FRW; Poznansky MC
Anticancer Drugs; 2017 Oct; 28(9):935-942. PubMed ID: 28817386
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
7. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
Davitt K; Babcock BD; Fenelus M; Poon CK; Sarkar A; Trivigno V; Zolkind PA; Matthew SM; Grin'kina N; Orynbayeva Z; Shaikh MF; Adler V; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2014; 44(3):241-8. PubMed ID: 25117093
[TBL] [Abstract][Full Text] [Related]
8. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals.
Sun B; Taha MS; Ramsey B; Torregrosa-Allen S; Elzey BD; Yeo Y
J Control Release; 2016 Aug; 235():91-98. PubMed ID: 27238443
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
11. MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.
Guo Y; Yuan J; Yin S; Wang X; Shuai R; Kang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1082-1087. PubMed ID: 28604448
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
Ayyagari VN; Diaz-Sylvester PL; Hsieh TJ; Brard L
PLoS One; 2017; 12(9):e0185111. PubMed ID: 28931042
[TBL] [Abstract][Full Text] [Related]
13. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
14. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.
Chen X; Gong L; Ou R; Zheng Z; Chen J; Xie F; Huang X; Qiu J; Zhang W; Jiang Q; Yang Y; Zhu H; Shi Z; Yan X
Gynecol Oncol; 2016 Mar; 140(3):537-44. PubMed ID: 26704638
[TBL] [Abstract][Full Text] [Related]
15. Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.
Thadi A; Morano WF; Khalili M; Babcock BD; Shaikh MF; Foster DS; Piazza Y; Gleeson EM; Goldstein E; Steele L; Campbell PM; Lin BO; Pincus MR; Bowne WB
Anticancer Res; 2021 Jan; 41(1):27-42. PubMed ID: 33419797
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
van Haaften C; Boot A; Corver WE; van Eendenburg JD; Trimbos BJ; van Wezel T
J Exp Clin Cancer Res; 2015 Apr; 34(1):38. PubMed ID: 25907439
[TBL] [Abstract][Full Text] [Related]
17. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
Haltia UM; Andersson N; Yadav B; Färkkilä A; Kulesskiy E; Kankainen M; Tang J; Bützow R; Riska A; Leminen A; Heikinheimo M; Kallioniemi O; Unkila-Kallio L; Wennerberg K; Aittokallio T; Anttonen M
Gynecol Oncol; 2017 Mar; 144(3):621-630. PubMed ID: 28104295
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
19. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
20. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
Dietrich CS; Greenberg VL; DeSimone CP; Modesitt SC; van Nagell JR; Craven R; Zimmer SG
Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
